Sep 2023 Articles

Articles
Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study
Wadström BN, Pedersen KM, Wulff AB, et al.
Journal:
Diabetologia

First published: September 30, 2023 DOI: 10.1007/s00125-023-06016-0
View
- Share
Articles
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström BN, Wulff AB, Pedersen KM, et al.
Journal:
Curr Atheroscler Rep

First published: September 28, 2023 DOI: 10.1007/s11883-023-01153-8
View
- Share
Articles
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial
Su Q, Liu Y, Zhang G, et al.
Journal:
Adv Ther

First published: September 28, 2023 DOI: 10.1007/s12325-023-02666-z
View
- Share
Articles
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review
Figtree GA, Vernon ST, Harmer JA, et al.
Journal:
J Am Coll Cardiol

First published: September 26, 2023 DOI: 10.1016/j.jacc.2023.06.045
View
- Share
Articles
Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics
Nicholls SJ, Bhatt DL, Buse JB, et al.
Journal:
Am Heart J

First published: September 25, 2023 DOI: 10.1016/j.ahj.2023.09.007
View
- Share
Articles
First clinical experiences with inclisiran in a real-world setting
Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE
Journal:
J Clin Lipidol

First published: September 18, 2023 DOI: 10.1016/j.jacl.2023.09.005
View
- Share
Articles
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial
Goodman SG, Steg PG, Poulouin Y, et al.
Journal:
J Am Heart Assoc

First published: September 13, 2023 DOI: 10.1161/JAHA.122.029216
View
- Share

Sep 2023 Articles

Articles

Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study

Wadström BN, Pedersen KM, Wulff AB, et al.

Articles

Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?

Wadström BN, Wulff AB, Pedersen KM, et al.

Articles

Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial

Su Q, Liu Y, Zhang G, et al.

Articles

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

Figtree GA, Vernon ST, Harmer JA, et al.

Articles

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

Nicholls SJ, Bhatt DL, Buse JB, et al.

Articles

First clinical experiences with inclisiran in a real-world setting

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE

Articles

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman SG, Steg PG, Poulouin Y, et al.

Articles

Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study

Wadström BN, Pedersen KM, Wulff AB, et al.

Share

Articles

Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?

Wadström BN, Wulff AB, Pedersen KM, et al.

Share

Articles

Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial

Su Q, Liu Y, Zhang G, et al.

Share

Articles

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

Figtree GA, Vernon ST, Harmer JA, et al.

Share

Articles

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

Nicholls SJ, Bhatt DL, Buse JB, et al.

Share

Articles

First clinical experiences with inclisiran in a real-world setting

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE

Share

Articles

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman SG, Steg PG, Poulouin Y, et al.

Share